Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
Filings by filing date
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 204 - 407 Downey Road SASKATOON SK S7N 4L8 |
Tel: | N/A |
Website: | https://www.zyus.com |
IR: | See website |
Key People | ||
Charlotte Moore Hepburn Chairman of the Board | Brent Zettl President, Chief Executive Officer | Michael D. Kindy Chief Financial Officer |
Business Overview |
ZYUS Life Sciences Corporation is a Canada-based life sciences company. The Company is focused on the global development and commercialization of cannabinoid-based pharmaceutical drug product candidates and exempt market therapeutics. Through clinical research, it is committed to furthering the understanding of cannabinoids with the clinical development of its pharmaceutical drug product candidates and intellectual property activities to protect its novel formulations. Additionally, the Company delivers cGMP / EU GMP-compliant cannabinoid products to patients through the exempt global medical market. The Company is also focused on commercialization of its exempt market therapeutics, such as cannabinoid oils, soft gel capsules and topical creams, in Canada and those international markets where medical cannabis is legal. |
Financial Overview |
For the nine months ended 30 September 2023, ZYUS Life Sciences Corp revenues increased from C$0K to C$254K. Net loss increased from C$350K to C$18.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Listing expense increase from C$0K to C$2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -C$0.07 to -C$0.29. |
Employees: | 2 as of Dec 31, 2005 |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $65.32M as of Sep 30, 2023 |
Annual revenue (TTM): | $0.25M as of Sep 30, 2023 |
EBITDA (TTM): | -$9.83M as of Sep 30, 2023 |
Net annual income (TTM): | -$18.12M as of Sep 30, 2023 |
Free cash flow (TTM): | -$15.25M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | $1.75M as of Sep 30, 2023 |
Shares outstanding: | 70,847,396 as of Jan 2, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |